Share price · ZLAB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ZLAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+12.7%
- 23 Oct 2026+9.0%
- 22 Oct 2026-8.9%
- 11 Aug 2026+10.3%
Nothing announced by ZLAB that day or the session before.
- 7 Aug 2026+11.7%
- 6 Aug 2026+13.7%
- 18 May 2026-8.4%
Nothing announced by ZLAB that day or the session before.
- 22 Apr 2026-6.4%
Nothing announced by ZLAB that day or the session before.
- 1 Apr 2026+8.1%
- 4 Mar 2026+8.7%
Nothing announced by ZLAB that day or the session before.
Share of unusual movement by asset
For each asset, the share of ZLAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
Adagrasib(Krazati) | Approved | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer |
Efgartigimod Alfa(Vyvgart) | Approved | FcRnAntibody fragment | Myasthenia GravisChronic Inflammatory Demyelinating Polyneuropathy Generalized Myasthenia Gravis |
| Approved | PARP1/2Small molecule | Non-Small Cell Lung CancerOvarian CancerGlioblastoma | |
| Approved | ROS1/NTRKSmall molecule | Non-Small Cell Lung CancerSolid Tumors ROS1-Positive Non-Small Cell Lung Cancer | |
Tisotumab Vedotin Humax-tf-adc(Tivdak) | Approved | Tissue Factor (TF)Antibody–drug conjugate | Non-Small Cell Lung CancerCervical Cancer |
Xanomeline/trospium chloride(Cobenfy) | Approved | Muscarinic M1/M4 receptor (agonist/antagonist combination)Small molecule | Alzheimer's DiseaseSchizophreniaBipolar Disorder |
| Phase 1 | IL-13 and IL-31 receptor A (IL-31RA)Multispecific antibody | Atopic Dermatitis |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(21 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
2027 (3)
2028 (8)
February 2028 (2)
June 2028 (1)
What to watch
September 2028 (3)
2029 (5)
March 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (2)
December 2029 (1)
What to watch
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $108M | $50M | $550M+ $10M short-term inv. | $46M-$58M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $106M | $62M | $608M+ $10M short-term inv. | $51M-$63M operating cash flow | report ↗ |
| 2026-Q1 | $100M | $66M | $761M | $51M | report ↗ |
| 2025-Q3 | $115M | $48M | $717M+ $0 short-term inv. | $36M-$32M operating cash flow | report ↗ |
| 2025-Q2 | $109M | $51M | $732M+ $0 short-term inv. | $41M-$31M operating cash flow | report ↗ |
| 2025-Q1 | $106M | $61M | $757M+ $0 short-term inv. | $48M-$62M operating cash flow | report ↗ |
| 2024-Q3 | $102M | $66M | $616M+ $0 short-term inv. | $42M-$27M operating cash flow | report ↗ |
| 2024-Q2 | $100M | $62M | $630M+ $0 short-term inv. | $80M-$42M operating cash flow | report ↗ |
| 2024-Q1 | $87M | $55M | $651M+ $0 short-term inv. | $53M-$90M operating cash flow | report ↗ |
| 2023-Q3 | $69M | $59M | $789M+ $32M short-term inv. | $69M-$55M operating cash flow | report ↗ |
| 2023-Q2 | $69M | $77M | $859M+ $16M short-term inv. | $121M-$59M operating cash flow | report ↗ |
| 2023-Q1 | $63M | $48M | $880M+ $51M short-term inv. | $49M-$69M operating cash flow | report ↗ |
| 2022-Q3 | $57M | $100M | $1.1B+ $0 short-term inv. | $161M-$126M operating cash flow | report ↗ |
| 2022-Q2 | $48M | $66M | $681M+ $575M short-term inv. | $138M-$45M operating cash flow | report ↗ |
| 2022-Q1 | $46M | $54M | $847M+ $465M short-term inv. | $82M-$87M operating cash flow | report ↗ |
| 2021-Q4 | $44M | — | $964M+ $445M short-term inv. | $212M-$153M operating cash flow | report ↗ |
| 2021-Q3 | $43M | $55M | $1.4B+ $170M short-term inv. | $96M-$161M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $457M | $221M | $680M+ $10M short-term inv. | $44M-$151M operating cash flow | report ↗ |
Zai Lab reported full-year 2025 product revenue of $457.18M, up 15.0% YoY from $397.61M, with R&D spend of $220.9M, down 5.8% YoY from $234.5M. Cash and equivalents stood at $679.57M, and the company recorded a net loss of $175.54M.
The company highlighted that zocilurtatug pelitecan is on track to be its first global oncology launch, with three registration-enabling studies planned across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026. It is also advancing ZL-1503, ZL-6201, ZL-1222, and ZL-1311, while KarXT was approved in China with commercial launch preparations underway. Pivotal readouts for povetacicept in IgAN and elegrobart in TED are expected in 2026, and the FDA approved Optune Pax for locally advanced pancreatic cancer.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $398M | $235M | $450M+ $330M short-term inv. | $64M-$215M operating cash flow | report ↗ |
| 2023-FY | $267M | $266M | $790M+ $16M short-term inv. | $84M-$198M operating cash flow | report ↗ |
| 2022-FY | $213M | $286M | $1.0B+ $0 short-term inv. | $111M-$368M operating cash flow | report ↗ |
| 2021-FY | $144M | $573M | $964M+ $445M short-term inv. | $176M-$549M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($99K), 39 sales ($11.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | GAYNOR RICHARD · director | Open-market purchase | 1,228 | $27.19 | $33K | Form 4 |
| 2026-10-01 | Chen Yajing · Chief Financial Officer | Option exercise | 920 | — | — | Form 4 |
| 2026-10-01 | Chen Yajing · Chief Financial Officer | Tax withholding | 315 | $25.50 | $8K | Form 4 |
| 2026-10-01 | Chen Yajing · Chief Financial Officer | Option exercise (derivative) | 920 | — | — | Form 4 |
| 2026-08-19 | Chen Yajing · Chief Financial Officer | Open-market sale | 260 | $27.00 | $7K | Form 4 |
| 2026-08-14 | Chen Yajing · Chief Financial Officer | Option exercise | 1,250 | — | — | Form 4 |
| 2026-08-14 | Chen Yajing · Chief Financial Officer | Tax withholding | 427 | $25.90 | $11K | Form 4 |
| 2026-08-14 | Chen Yajing · Chief Financial Officer | Option exercise (derivative) | 1,250 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 98 reporting institutions held 28.2M shares ($515.7M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 6,574,032 | $123.7M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5,707,262 | $107.4M |
| 3 | Frazier Life Sciences Management, L.P. | 1,902,320 | $35.8M |
| 4 | CITADEL ADVISORS LLC | 1,688,632 | $31.8M |
| 5 | BAMCO INC /NY/ | 1,658,318 | $31.2M |
| 6 | ADAR1 Capital Management, LLC | 1,425,367 | $26.8M |
| 7 | FMR LLC | 1,262,391 | $23.7M |
| 8 | BlackRock, Inc. | 865,146 | $16.3M |
| 9 | Rock Springs Capital Management LP | 814,707 | $15.3M |
| 10 | UBS Group AG | 504,191 | $9.5M |
| 11 | B Group, Inc. | 450,646 | $8.5M |
| 12 | SCHRODER INVESTMENT MANAGEMENT GROUP | 393,167 | $7.0M |
| 13 | NAN FUNG TRINITY (HK) LTD | 346,466 | $6.5M |
| 14 | TWO SIGMA INVESTMENTS, LP | 309,723 | $5.8M |
| 15 | SUPERSTRING CAPITAL MANAGEMENT LP | 275,818 | $5.2M |